PHILADELPHIA, PA—A recent study comparing the efficacy and safety of ceftaroline vs. vancomycin in obese (BMI ≥30) and non-obese (BMI <30) patients found that ceftaroline therapy was associated with similar clinical cure rates in both non-obese as well as among obese patients, when compared with vancomycin (with or without gram-negative coverage combination therapy) in patients with skin and soft tissue infections (SSTI), according to data presented at IDWeek 2014.

Hao Nguyen, MD, of the Department of Internal Medicine Infectious Diseases Division, East Carolina University- Brody School of Medicine, Greenville, NC, said that a prior study evaluating the safety and efficacy of ceftaroline vs. vancomycin plus aztreonam in SSTI showed that clinical cure rates were similar for ceftaroline compared with vancomycin plus aztreonam.  However, the majority of the patient population in the study was non-obese and little was known regarding the efficacy of ceftaroline in patients with BMI >30.

Dr. Nguyen and colleagues undertook a retrospective study to compare the efficacy and safety of ceftaroline in a population with normal BMI compared with those with BMI ≥30. Of 244 patients, 134 received ceftaroline and 110 received vancomycin with or without gram-negative coverage therapy. Baseline characteristics of the treatment groups were comparable. Among 134 patients in the ceftaroline group, 84 were obese patients (62.7%). In addition, clinical improvements were similar between obese and non-obese patients (96% vs. 95.2%).

Among 110 patients treated with vancomycin, there were 85 obese patients (77.3%). When compared with vancomycin in non-obese, clinical cure rate was similar for those treated with ceftaroline (95.2% vs. 97.6%). However, researchers noted a higher incidence of acute kidney injury in obese patients treated with vancomycin (7.06% vs. 0%, P=0.026).

“The cure rates consistently exceeded 93% in both obese and normal BMI population,” concluded Dr. Nguyen. He added that future studies evaluating patients with osteomyelitis, bacteremia, and endocarditis are needed to “supplement the current understanding of the clinical use of ceftaroline.”